| Bioactivity | JAK-IN-30 (compound 31) is a water-soluble JAK inhibitor with IC50 values of 2, 15, 18 and 2 nM for JAK2, JAK1, JAK3 and TYK2, respectively. JAK-IN-30 has research potential for dry eye disease (DED)[1]. |
| Name | JAK-IN-30 |
| CAS | 2891469-99-9 |
| Formula | C19H26N8S |
| Molar Mass | 398.53 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Gordhan HM, et al. Eyes on Topical Ocular Disposition: The Considered Design of a Lead Janus Kinase (JAK) Inhibitor That Utilizes a Unique Azetidin-3-Amino Bridging Scaffold to Attenuate Off-Target Kinase Activity, While Driving Potency and Aqueous Solubility. J Med Chem. 2023 Jul 13;66(13):8929-8950. |
JAK-IN-30
CAS: 2891469-99-9 F: C19H26N8S W: 398.53
JAK-IN-30 (compound 31) is a water-soluble JAK inhibitor with IC50 values of 2, 15, 18 and 2 nM for JAK2, JAK1, JAK3 and
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.